Matthew J. Reilly, P.C.
Overview
Matt Reilly is a partner in the Washington, D.C., office of Kirkland & Ellis LLP. Matt is one of the preeminent antitrust practitioners in the country. Matt’s practice focuses on a wide range of antitrust matters, including antitrust litigation, complex transactions and antitrust counseling and government investigations. He is regularly relied on by major clients to navigate the approval process for the most complex, high-profile transactions, and to prepare to litigate mergers that face steep resistance from the agencies.
Matt has led over a dozen agency-litigated merger challenges, representing either the FTC or the merging parties. During his many years in senior roles at the FTC, Matt led many of the agency’s most prominent merger matters and, as a result of his litigation achievements, received the Commission’s highest recognition, the Chairman’s Award. More recently, in the last ten years alone, Matt has been brought into more than ten merger investigations post-Second Request to supplement existing counsel to obtain deal approval after the FTC or DOJ has signaled serious concerns, to prepare for litigation, and, if necessary, to litigate the deal on behalf of the merging parties. Matt is one of a very small number of active antitrust attorneys to have led as first-chair trial counsel successful merger trials both for and against the federal enforcement agencies. As a result of his career accomplishments, Matt was recently elected into the five-member inaugural class of Legal 500’s Antitrust Merger Control Hall of Fame as one of its youngest members. One prominent client describes Matt simply as “the fixer — their first and clear choice for a deal that is facing a really tough fight” at the agency or in litigation.
Matt also frequently assists clients navigating non-merger litigations and investigations. His experience includes securing unconditional closure of multiple FTC and DOJ Sherman Act investigations, and his clients in this area include several Fortune 100 technology and health care companies. Matt was recently retained by two Fortune 20 companies to take a leading role in high-stakes agency conduct investigations.